Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes

被引:30
|
作者
Humar, Abhinav [1 ]
Crotteau, Shaina [1 ]
Gruessner, Angelika [1 ]
Kandaswamy, Raja [1 ]
Gruessner, Rainer [1 ]
Payne, William [1 ]
Lake, John [1 ]
机构
[1] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA
关键词
immunosuppression; liver transplant; post-transplant diabetes; steroid avoidance;
D O I
10.1111/j.1399-0012.2007.00683.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoinunune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%. p = 0.004). Conclusions: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.
引用
收藏
页码:526 / 531
页数:6
相关论文
共 50 条
  • [31] Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update
    Rodriguez-Rodriguez, Ana Elena
    Porrini, Esteban
    Hornum, Mads
    Donate-Correa, Javier
    Morales-Febles, Raul
    Khemlani Ramchand, Simran
    Molina Lima, Maria Xixiang
    Torres, Armando
    NEPHRON, 2021, 145 (04) : 317 - 329
  • [32] Post-transplant Diabetes Mellitus in Kidney Transplant Recipients: A Multicenter Study
    Malik, Rubab F.
    Jia, Yaqi
    Mansour, Sherry G.
    Reese, Peter P.
    Hall, Isaac E.
    Alasfar, Sami
    Doshi, Mona D.
    Akalin, Enver
    Bromberg, Jonathan S.
    Harhay, Meera N.
    Mohan, Sumit
    Muthukumar, Thangamani
    Schroppel, Bernd
    Singh, Pooja
    Weng, Francis L.
    Philbrook, Heather R. Thiessen
    Parikh, Chirag R.
    KIDNEY360, 2021, 2 (08): : 1296 - 1307
  • [33] Impact of pre-transplant cardiac risk factor burden on post-transplant events in liver transplant recipients
    Lasco, R.
    Manuli, C.
    Saracco, M.
    Lavezzo, B.
    Ottobrelli, A.
    Cocchis, D.
    Romagnoli, R.
    Martini, S.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S43 - S43
  • [34] Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1561 - 1562
  • [35] Management of Post-Liver Transplant Recurrence of Hepatitis C
    Justin Taylor
    Paula Cox-North
    Charles S. Landis
    Drugs, 2016, 76 : 1711 - 1717
  • [36] Management of Post-Liver Transplant Recurrence of Hepatitis C
    Taylor, Justin
    Cox-North, Paula
    Landis, Charles S.
    DRUGS, 2016, 76 (18) : 1711 - 1717
  • [37] The predictors of post-transplant coronary events among liver transplant recipients
    Malik, Mohammad U.
    Russell, Stuart D.
    Pustavoitau, Aliaksei
    Chacko, Matthews
    Cosar, Arif M.
    Thompson, Carol B.
    Trilianos, Panagiotis
    Dagher, Nabil N.
    Cameron, Andrew M.
    Gurakar, Ahmet
    HEPATOLOGY INTERNATIONAL, 2016, 10 (06) : 974 - 982
  • [38] Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
    Hector Rodriguez-Luna
    Hugo E. Vargas
    Pratima Sharma
    Jose Ortiz
    Giovanni De Petris
    Vijayan Balan
    Thomas Byrne
    Adyr Moss
    David Mulligan
    Jorge Rakela
    David D. Douglas
    Digestive Diseases and Sciences, 2004, 49 : 38 - 41
  • [39] Hypomagnesemia and risk of post-transplant lymphoproliferative disorder in liver transplant recipients
    Mahale, Parag
    Mckenna, Gregory J.
    Saracino, Giovanna
    Jennings, Linda
    Mbulaiteye, Sam M.
    Klintmalm, Goran B.
    Engels, Eric A.
    TRANSPLANT INTERNATIONAL, 2020, 33 (12) : 1835 - 1836
  • [40] Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study
    Lo, Regina Cheuk-lam
    Chan, See-ching
    Chan, Kwong-leung
    Chiang, Alan Kwok-shing
    Lo, Chung-mau
    Ng, Irene Oi-lin
    JOURNAL OF CLINICAL PATHOLOGY, 2013, 66 (05) : 392 - 398